HeartBeam, Inc. (BEATW)
| Market Cap | 47.12M -20.2% |
| Revenue (ttm) | n/a |
| Net Income | -20.23M |
| EPS | -0.56 |
| Shares Out | 55.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0709 |
| Previous Close | n/a |
| Day's Range | 0.0524 - 0.0709 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About BEATW
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]
News
HeartBeam price target lowered to $2.50 from $5.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on HeartBeam (BEAT) to $2.50 from $5.50 and keeps a Buy rating on the shares post the Q1 report. The firm believes the…
HeartBeam price target lowered to $5 from $8 at Benchmark
Benchmark lowered the firm’s price target on HeartBeam (BEAT) to $5 from $8 and keeps a Speculative Buy rating on the shares after “a solid update” provided with Q1 results.
HeartBeam Earnings Call Transcript: Q1 2026
Achieved key milestones in commercialization, clinical validation, and product development, including flagship accounts in four major geographies and a strategic AI partnership. Q1 2026 saw a 19% year-over-year reduction in cash burn, with a strengthened balance sheet and funding runway into 2027.
HeartBeam Quarterly report: Q1 2026
HeartBeam has published its Q1 2026 quarterly earnings report on May 13, 2026.
HeartBeam Slides: Q1 2026
HeartBeam has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
HeartBeam Earnings release: Q1 2026
HeartBeam released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
HeartBeam reports Q1 EPS (12c) vs. (18c) last year
“In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we’ve consistently discussed over the last several quarters. ...
HeartBeam Reports First Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results.
HeartBeam initiates pilot study of first on-demand 12-lead ECG patch
HeartBeam (BEAT) announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two…
HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic.
HeartBeam announces commercial agreement with Atelier Health
HeartBeam (BEAT) announced a commercial agreement with Atelier Health, a concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based A...
HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice.
HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time.
HeartBeam downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital downgraded HeartBeam (BEAT) to Hold from Buy without a price target following the company’s’ capital raise. The “deal size and terms represent a strategic misstep,” the analyst…
HeartBeam Announces Closing of $10 Million Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of $10 Million Public Offering of Common Stock.
HeartBeam Slides: Investor presentation
HeartBeam has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.
HeartBeam 12.5M share Spot Secondary priced at 80c
Titan Partners acted as sole book running manager for the offering.
HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock.
HeartBeam announces common stock offering, no amount given
HeartBeam (BEAT) announced that it is commencing an underwritten public offering of shares of its common stock. All of the securities to be sold in the proposed offering will be…
HeartBeam Announces Proposed Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Proposed Public Offering of Common Stock.
HeartBeam initiated with a Buy at B. Riley
B. Riley initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free…
HeartBeam initiated with a Buy at Stifel
Stifel initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free device…
HeartBeam initiated with a Buy at D. Boral Capital
D. Boral Capital initiated coverage of HeartBeam (BEAT) with a Buy rating and $5 price target The company’s novel ambulatory electrocardiogram platform aims to replicate the diagnostic capability of a...
HeartBeam Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
A novel at-home 12-lead ECG platform is launching with a subscription model targeting concierge cardiology, leveraging strong physician and patient demand. The company is expanding into ambulatory monitoring and AI-driven cardiac care, supported by clinical studies and strategic partnerships.
HeartBeam Registration statement: Registration Filing
HeartBeam filed a registration statement on March 13, 2026, providing details about a securities offering with the SEC.